A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
SUMMARY The gut hormone PYY3–36 reduces food intake in humans and exhibits at least additive efficacy in combination with GLP-1. However, the utility of PYY analogs as anti-obesity agents has been severely limited by emesis and rapid proteolysis, a profile similarly observed with native PYY3–36 in obese rhesus macaques. Here, we found that antibody conjugation of a cyclized PYY3–36 analog achieved high NPY2R selectivity, unprecedented in vivo stability, and gradual infusion-like exposure. These properties permitted profound reduction of food intake when administered to macaques for 23days without a single emetic event in any animal. Co-administration with the GLP-1 receptor agonist liraglutide for an additional 5 days further reduced food intake with only one animal experiencing a single bout of emesis. This antibody-conjugated PYY analog therefore may enable the long-sought potential of GLP-1/PYY-based combination treatment to achieve robust, well-tolerated weight reduction in obese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855 · cited 1×
“Obesity is associated with numerous comorbidities, including diabetes, hypertension, cardiovascular disease, cancer, Alzheimer’s disease, and osteoarthritis (Guh et al., 2009).”
BackgroundMechanisms, Pathophysiology, and Management of Obesity
Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1514009 · Cited by 1,867
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1×
“Exceptions such as lixisenatide, however, highlight the contribution of additional factors to GI tolerability, such as potency, access to CVO in the brain that regulate nausea and appetite, dose, and background medication (Bettge et al., 2017).”
BackgroundGLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290 · cited 1×
“GLP-1 reduces FI at least in part via hypothalamic and hindbrain pathways (Kanoski et al., 2016).”
BackgroundKievit, P., Halem, H., Marks, D. L., Dong, J. Z., Glavas, M. M., Sinnayah, P., Pranger, L., Cowley, M. A., Grove, K. L., & Culler, M. D. (2013) · Diabetes · doi:10.2337/db12-0598 · Cited by 231 · cited 3×
“Based on previous studies on food intake and body weight loss using similar centrally mediated mechanisms (Kievit et al., 2013a; Andersen et al., 2018), group sizes of 10 animals will provide for >90% power using repeated measures ANOVA for both food intake and body weight measurements.”
BackgroundMethodInfluentialEfficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1806 · Cited by 163 · cited 1×
“This inability to separate FI from emesis has undermined the development of PYY-based therapeutics for obesity (Gantz et al., 2007).”
BackgroundAndersen, B., Straarup, E. M., Heppner, K. M., Takahashi, D. L., Raffaele, V., Dissen, G. A., Lewandowski, K., Bödvarsdottir, T. B., Raun, K., Grove, K. L., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0080-7 · Cited by 66 · cited 2×
“Based on previous studies on food intake and body weight loss using similar centrally mediated mechanisms (Kievit et al., 2013a; Andersen et al., 2018), group sizes of 10 animals will provide for >90% power using repeated measures ANOVA for both food intake and body weight measurements.”
BackgroundMethodSelf-citation
Cited by
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators
Han, H., Yi, B., Zhong, R., Wang, M., Zhang, S., Ma, J., Yin, Y., Yin, J., Chen, L., & Zhang, H. (2021) · Microbiome · doi:10.1186/s40168-021-01093-y · Cited by 292
Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000612 · Cited by 42
Appetite control: Hormones or diet strategies?
Freire, R. H., & Alvarez-Leite, J. I. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000675 · Cited by 37
Metadata
- Authors
- Rangwala, S. M., D’Aquino, K., Zhang, Y.-M., Bader, L., Edwards, W., Zheng, S., Eckardt, A., Lacombe, A., Pick, R., Moreno, V., Kang, L., Jian, W., Arnoult, E., Case, M., Jenkinson, C., Chi, E., Swanson, R. V., Kievit, P., Grove, K., Macielag, M., Erion, M. D., SinhaRoy, R., & Leonard, J. N.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 29
- Issue
- 4
- Pages
- 837-843.e5
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2912933215
- Cited by
- 65
- References
- 8
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates. https://app.cochat.ai/papers/10.1016/j.cmet.2019.01.017
- The paper
- Rangwala, S. M., D’Aquino, K., Zhang, Y.-M., Bader, L., Edwards, W., Zheng, S., Eckardt, A., Lacombe, A., Pick, R., Moreno, V., Kang, L., Jian, W., Arnoult, E., Case, M., Jenkinson, C., Chi, E., Swanson, R. V., Kievit, P., Grove, K., . . . Leonard, J. N. (2019). A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates. Cell Metabolism. https://doi.org/10.1016/j.cmet.2019.01.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.